PHILADELPHIA, Oct. 24, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, October 27, 2011 at 2:00 p.m. (Eastern Time). In response to stockholder interest, the Company will host a call to provide a status report on Ampligen® as a treatment for Chronic Fatigue Syndrome (CFS). Management will provide a briefing and answer questions regarding the Company's pending New Drug Application (NDA) and the related Food and Drug Administration (FDA) Complete Response Letter. The Company will update scientific advances in Chronic Fatigue Syndrome and give an overview of new data of a potential diagnostic/prognostic blood test developed with Chronix Biomedical based on novel gene patterns identified in peripheral blood of CFS patients.
Company executives will conduct a question and answer session following their remarks.
To access the conference call:
U.S. Callers: 800-346-7359
International Callers: 973-528-0008
Conference Entry Code: 27781
This call will be webcast via the Company's website at: http://www.hemispherx.net.
The webcast and a digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until November 10, 2011 by dialing:
U.S. Callers: 800-332-6854
International Callers: 973-528-0005
Conference Entry Code: 27781
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of pre-clinical or clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.